论文部分内容阅读
目的:探讨复方丹参逆转地中海贫血肝纤维化的临床效果。方法:选取我院2013年6月~2016年1月儿科收治的60例地中海贫血合并肝纤维化患儿作为研究对象。按照入院顺序随机分为观察组30例与对照组30例,观察组应用复方丹参联合去铁胺治疗,对照组仅应用去铁胺治疗。对比两组临床治疗效果及治疗前后患儿血清肝纤维化指标变化情况。结果:观察组治疗后肝脏超声结果优于对照组,差异具有统计学意义(P<0.05)。观察组治疗后肝纤维指标变化优于对照组,差异具有统计学意义(P<0.05)。结论:临床上对地中海贫血合并肝纤维化患儿应用复方丹参联合去铁胺治疗,肝纤维化程度显著改善,有助于提高患儿生存质量及生存周期,值得临床推广。
Objective: To investigate the clinical effect of compound Salvia miltiorrhiza on the reversal of liver fibrosis in patients with thalassemia. Methods: Sixty children with thalassemia and hepatic fibrosis admitted to our hospital from June 2013 to January 2016 were selected as the study subjects. According to the order of admission, 30 cases were randomly divided into the observation group and the control group. The observation group was treated with compound Danshen combined with deferoxamine and the control group with deferoxamine only. Comparison of two groups of clinical treatment and treatment of children before and after changes in serum indicators of liver fibrosis. Results: The results of liver ultrasound in observation group were better than those in control group, the difference was statistically significant (P <0.05). The change of liver fibrosis index in the observation group was better than that in the control group, the difference was statistically significant (P <0.05). Conclusion: The clinical application of compound Danshen combined with deferoxamine in children with thalassemia and liver fibrosis can significantly improve the degree of liver fibrosis, which will help to improve the quality of life and life cycle of children with dementia. It is worthy of clinical promotion.